{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:54:25Z","timestamp":1791428065086,"version":"4.3.3"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Providing treatment to all people living with HIV (PLHIV), a strategy known as treatment as prevention, is a highly effective intervention against HIV. Policies that reduce access to antiretroviral therapy (ART), an important component of treatment-as-prevention (TasP) strategies, might undermine decades of HIV control in the US and result in thousands of new HIV infections.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the association between TasP and the HIV epidemic in the US from 2011 to 2025 and to project the outcomes of a potential rollback of this policy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this decision analytical model, HIV incidence and prevalence from 2011 to 2030 were simulated. PLHIV were stratified by transmission group (men who have sex with men, heterosexual men, heterosexual women, and people who inject drugs) and stage of the HIV care cascade (undiagnosed, diagnosed but not receiving ART, receiving ART with detectable viremia, and receiving ART and virally suppressed).<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Change in HIV care cascade.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Annual HIV transmissions from 2011 to 2025 were compared with HIV care cascade (1) following the observed trend (with TasP) or (2) fixed at 2011 levels, without TasP. The impact of preexposure prophylaxis (PreP) rollout since 2017 was also estimated. Finally, HIV transmission from 2026 to 2030 was projected assuming that (1) 10% to 30% of PLHIV immediately lose ART access, reflecting the estimated share of ART funded through federal subsidies, (2) no change, or (3) a moderate increase in ART access.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In 2011, there were 1\u202f008\u202f300 PLHIV. In 2025, treatment as prevention was associated with an estimated 44.5% reduction in HIV incidence; PrEP, a 20.5% reduction; and treatment as prevention plus PrEP, a 61.8% reduction. From 2011 to 2025, TasP averted an estimated 197\u202f400 new HIV acquisitions in the US, PrEP averted 33\u202f200, and the 2 combined averted 293\u202f200. Immediate losses of ART access affecting 10%, 20%, or 30% of treated PLHIV were associated with approximately 35\u202f900, 81\u202f700, and 111\u202f200 additional HIV acquisitions between 2026 and 2030, respectively, substantially reversing the population-level gains achieved through TasP.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this decision analytical model estimating the potential effects of reductions in ART access, findings suggest that these reductions will not only jeopardize individual health outcomes and over a decade of progress toward HIV elimination but also result in thousands of new HIV acquisitions over the next 5 years.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.30330","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:30:32Z","timestamp":1787326232000},"page":"e2630330","source":"Crossref","is-referenced-by-count":1,"title":["Treatment as Prevention and HIV Transmission in the US"],"prefix":"10.1001","volume":"9","author":[{"given":"Laura","family":"Matrajt","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Department of Applied Mathematics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Stansfield","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Moore","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Donnell","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Department of Global Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobromir","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Department of Applied Mathematics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"6","key":"zoi260828r1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy.","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260828r2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV Transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"zoi260828r3","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S2352-3018(18)30132-2","article-title":"Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.","volume":"5","author":"Bavinton","year":"2018","journal-title":"Lancet HIV"},{"issue":"10189","key":"zoi260828r4","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"zoi260828r7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States.","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"zoi260828r11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1812281","article-title":"Universal testing, expanded treatment, and incidence of HIV infection in Botswana.","volume":"381","author":"Makhema","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260828r13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0169-2070(92)90055-E","article-title":"Modeling and forecasting U.S. sex differentials in mortality.","volume":"8","author":"Carter","year":"1992","journal-title":"Int J Forecast"},{"issue":"1","key":"zoi260828r14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QAI.0000000000003017","article-title":"HIV incidence in Botswana rural communities with high antiretroviral treatment coverage: results from the Botswana combination prevention project, 2013-2017.","volume":"91","author":"Ussery","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"zoi260828r16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.7326\/ANNALS-25-01737","article-title":"The Potential impact of ending the Ryan White HIV\/AIDS program on HIV incidence: a simulation study in 31 U.S. cities.","volume":"178","author":"Forster","year":"2025","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi260828r17","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1016\/S2352-3018(25)00036-0","article-title":"Association of state-level PrEP coverage and new HIV diagnoses in the USA from 2012 to 2022: an ecological analysis of the population impact of PrEP.","volume":"12","author":"Sullivan","year":"2025","journal-title":"Lancet HIV"},{"key":"zoi260828r18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6811e1","article-title":"Vital signs: HIV transmission along the continuum of care\u2014United States, 2016.","volume":"68","author":"Li","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi260828r5","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Accessed April 3, 2026. https:\/\/www.who.int\/publications\/i\/item\/9789241509565"},{"key":"zoi260828r6","unstructured":"US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2016. Accessed July 13, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586306\/"},{"key":"zoi260828r8","unstructured":"HIV.gov. What is \u2018ending the HIV epidemic: a plan for America\u2019? Accessed April 3, 2026. https:\/\/www.hiv.gov\/ending-hiv-epidemic"},{"key":"zoi260828r9","unstructured":"Dawson? L, Kates? J. Constrained budgets lead states to restrict HIV drug access through Ryan White. KFF. March 2, 2026. Accessed April 3, 2026. https:\/\/www.kff.org\/hiv-aids\/constrained-budgets-lead-states-to-restrict-hiv-drug-access-through-ryan-white\/"},{"key":"zoi260828r10","unstructured":"Mandavilli? A. States move to limit access to HIV treatment. The New York Times. March 2, 2026. Accessed April 3, 2026. https:\/\/www.nytimes.com\/2026\/03\/02\/health\/hiv-drugs-ryan-white.html"},{"key":"zoi260828r12","unstructured":"US Centers for Disease Control. AtlasPlus\u2014tables. Accessed April 3, 2026. https:\/\/gis.cdc.gov\/grasp\/nchhstpatlas\/tables.html"},{"key":"zoi260828r15","unstructured":"World Health Organization. Eswatini steps up progress towards zero new HIV infection status by 2030. March 31, 2026. Accessed April 3, 2026. https:\/\/www.afro.who.int\/photo-story\/eswatini-steps-progress-towards-zero-new-hiv-infection-status-2030"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853156\/matrajt_2026_oi_260828_1790956383.67672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:00:53Z","timestamp":1791385253000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.30330","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}